Specialty & fine chemicals

Bio-based dyes and pigments produced via microbial fermentation and synthetic biology.

Bio-derived solvents — ethyl lactate from fermented lactic acid (Corbion's Biviture brand, Galactic's Galactic bio-solvents line, Vertec Biosolvents' corn-based MEK-replacements now under Shrieve Chemical ownership) and bioethanol-derived ethyl acetate — replacing MEK, toluene and xylene in paints, coatings, industrial degreasing and pharma processing, alongside BASF's biomass-balanced BMBcert intermediates that attribute renewable carbon into existing solvent families via mass-balance accounting — a mature commercial niche with no dedicated Chinese or Indian originator confirmed as of 2026.

Microbial surface-active glycolipids (rhamnolipids, sophorolipids, MELs) produced by aerobic fermentation of plant oils and sugars — biodegradable, low-toxicity replacements for petrochemical surfactants in detergents, personal care, agchem and enhanced oil recovery.

Producing CBD, THC and rare cannabinoids (CBG, CBDV, THCV) as platform molecules via engineered yeast fermentation and chemo-enzymatic synthesis, bypassing plant cultivation.

Capsaicin — the pungent capsaicinoid of Capsicum peppers — is at the intersection of plant-cell biotechnology (Debut's cultivation-free fermentation), precision-fermentation flavour modulation (DSM-Firmenich, Givaudan) and a centuries-old capsicum-oleoresin extraction base anchored in India by Plant Lipids; fermentation-route biosynthesis remains emerging while extraction still dominates global supply.

Cocoa-price shocks (West African drought, CSSV crop disease, prices above $10,000/tonne) and the EU Deforestation Regulation have pulled real B2B capital into cocoa-free alternatives: Planet A Foods' oat/sunflower ChoViva now supplies Mars (May 2026 launch) and Lufthansa; Cargill distributes Voyage Foods' sunflower/grape-seed NextCoa across North America (also launched May 2026); WNWN Food Labs (UK) ferments barley and carob into its Waim! bars; and California Cultured's cell-cultured cocoa biomass remains pilot-scale, pending an FDA GRAS dossier. No Chinese commercial originator (Jiangnan University's cocoa-butter-equivalent yeast research, Bota Biosciences, Bluepha) cleared source confirmation as of 2026.

Microbial precision fermentation of hyaluronic acid to a defined molecular weight and pharmacopoeia-grade purity — a B2B biopolymer API for ophthalmic viscoelastics, dermal fillers, orthopedic viscosupplementation and premium cosmetics, under FDA, EMA and NMPA oversight.

L-menthol supply in 2026 is dominated by conventional routes under active capacity expansion — BASF's triple-digit-million-euro world-scale menthol/linalool plant at Ludwigshafen (Apr 2026) and Symrise's 50-year synthetic-menthol franchise in the EU, alongside NMPA-licensed API extraction (Huangshan Tianmu Mint Pharmaceutical, license renewed to 2030) and food-grade dispersion formulation (Jiangsu Caiwei, 0.001-0.5% precision dosing) in China — while dedicated fermentation-route biosynthesis remains at the academic/patent stage with no company-specific commercial originator confirmed.

The confirmed 2026 commercial market for non-animal musk is dominated by established macrocyclic ketone/lactone brands — Givaudan's Velvione (a 16-membered macrocyclic musk ketone) and DSM-Firmenich's Exaltolide — plus IFF's newly launched Orionide Oliffac clean-musk line (unveiled at SIMPPAR 2026) and, in China, Beijing Lianxin Pharmaceutical's state-designated Class-1 artificial-musk substitute for traditional-medicine use (founded 1999, National S&T Progress Award), while the engineered-yeast fermentation route described in early research (omega-oxidation, lipase-catalyzed macrocyclization) remains at the patent-application stage with no confirmed commercial fermentation-musk originator.

Yeast- and algae-fermented triglyceride oils that reproduce the fatty-acid profile of palm oil, offering deforestation-free B2B fats for food, cosmetics and biofuels.

High-value molecules — flavors, fragrances, food ingredients and bio-based monomers — produced by precision fermentation, biocatalysis and lignocellulose biorefinery from renewable carbon instead of petrochemicals or extraction.

Theobromine (3,7-dimethylxanthine) — cocoa's signature xanthine alkaloid — is sourced today from cocoa-processing byproducts (Cargill) and methylxanthine API manufacturing (Bajaj Healthcare, CSPC Innovation Pharma), while precision-fermentation and deforestation-free molecular synthesis (DSM-Firmenich, Fermtech) emerge under EU Deforestation Regulation pressure; this article covers the pure molecule, distinct from cocoa-free chocolate alternatives.

Fermentation-derived hyaluronic acid, recombinant collagen, bio-squalane and ingestible actives replacing animal- and petrochemical-derived cosmetic ingredients across China, the US and the EU.

Cosmetic bio-actives — prebiotics, postbiotics and bacterial lysates — and biome-friendly bases that nourish the skin's commensal flora (not live drugs): a fast-growing clean-beauty segment built on 16S rRNA profiling and selective preservation.

Recombinant and next-generation engineered botulinum neurotoxins (BoNT) — expressed via DNA technology or reformulated as complex-free / ready-to-use liquids — are displacing traditional Clostridium botulinum fermentation: AbbVie/Allergan's Boey® (trenibotulinumtoxinE, recombinant serotype E) won EU and Health Canada approval in 2026 with onset as early as 8 hours and a 2-3 week duration across 2,100+ Phase 3 patients; Galderma's Relfydess™ (relabotulinumtoxinA, PEARL™ Technology ready-to-use liquid) reached 33 markets including EU approval across 16 countries in 2026; Merz's Xeomin (incobotulinumtoxinA, complexing-protein-free naked toxin) holds 79-country approval; Eirion's AI-09 ready-to-use recombinant liquid injectable achieved 6-month duration at the highest dose in a 96-subject Phase 1-2 trial. China's Lanzhou/CNBG Hengli® (衡力) — the country's first domestic BoNT-A (2002 approval, 30+ years lineage) — leads the local market with first-in-China 2025-2026 approvals for axillary hyperhidrosis and benign masseter hypertrophy while domestic recombinant R&D remains pre-commercial.

Recombinant human serum albumin (rHSA) replaces plasma-derived HSA (pHSA) — constrained by donor blood supply and viral contamination risk since the 1940s — with biosynthetic production in yeast (Pichia pastoris, Hansenula polymorpha) or plant (rice endosperm) hosts: Healthgen Biotech's OsrHSA (奥福民®) became the world's first NMPA-approved rHSA injection (July 2025) with 1-million-vial annual capacity and a 22-centre Phase III in decompensated liver cirrhosis; InVitria's Exbumin (rice-derived, ExpressTec platform) is the excipient in Merck's ERVEBO Ebola vaccine — the first FDA/EMA/PMDA-approved rice rHSA in an injectable — and Optibumin 25 (launched April 2025) is the first recombinant 25% HSA for closed-system biomanufacturing; Proliant launched AlbufreeDX (June 24, 2026) for diagnostics; Basic Pharma (NL) + ARTES Biotechnology (DE) make Hansenula polymorpha rHSA; Shilpa Medicare's sRbumin® became India's first rHA Phase 1 completion (August 2024), with CDSCO Phase III nod (November 2024) and an Orion Europe commercialization deal. The global rHSA market stood at USD 166M in 2025, projected to USD 421M by 2035 (CAGR 9.75%).

Recombinant silk fibroin and spider-silk proteins — expressed via microbial precision fermentation (Spiber Brewed Protein™, AMSilk Biosteel, Bolt Threads MicroSilk), transgenic *Bombyx mori* silkworms (Kraig Biocraft MaSp1/MaSp2), or purified from *Bombyx mori* cocoons for biomaterials (Sofregen Medical SilkVoice FDA-cleared ENT device) — have crossed into commercial scale in 2026: Spiber's Rayong Thailand plant and 2025 Italian-mill partnerships (Botto Giuseppe, Manifattura Sesia, Achille Pinto) produced 100% Brewed Protein yarns at industrial tonnage; AMSilk's bioengineered yarns debuted in Balenciaga Spring 2026 collection and Ajinomoto Foods Europe's dedicated 160 m³ Nesle France fermentation plant came online July 2026; Kraig Biocraft hit 1.3 metric tons of recombinant spider silk cocoons in March 2026 (1.8 MT in April) via transgenic silkworms in Vietnam; Sofregen Medical's SilkVoice holds two FDA 510(k) clearances (K180631, K240919) for vocal cord medialization, validated in a 33-patient Laryngoscope 2026 study. Bolt Threads patented recombinant silk polypeptide as a silicone replacement in personal care (US20260069524A1, March 2026).